System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish 1 citation

PubMed: 38326179 DOI: 10.1016/j.htct.2024.01.001

Consensus of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy (ABHH) and the Brazilian Ministry of Health - General management of blood and blood products on the tests necessary for the release of exceptional medicines for sickle cell disease.

Hematol Transfus Cell Ther 46(1):67-71

Authors: Clarisse Lobo, Aderson Araújo, Alexandre de Albuquerque Antunes, Ana Cristina Silva Pinto, Ariadne Carvalho Godinho, Cassia Silvestre Mariano Pires, Cinthia Cristina Matheus, Xerez de Albuquerque, Daniele Campos Fontes Neves, Fábio de Lima Moreno, Giorgio Baldanzi, Grazziella Curado Siufi, Heloisa Helena Pereira Miranda, Jane Hankins, Joice Aragão, Josefina Aparecida Pellegrini Braga, Juliana Touguinha Neves Martins, Luciana Campos Costa Machado de Souza, Maria Stella Figueiredo, Mirella Rodrigues Oliveira, Patricia Santos Resende Cardoso, Patricia Costa Alves Pinto, Patricia Gomes Moura, Rodolfo Delfini Cançado, Paulo Ivo Cortez de Araujo, Sara Olalla Saad, Sandra Regina Loggetto, Teresa Cristina Cardoso Fonseca

Affiliations

  • Hemocentro Coordenador do Estado do Rio de Janeiro (HEMORIO), Rio de Janeiro, RJ, Brazil.
  • Fundação de Hematologia e Hemoterapia de Pernambuco (HEMOPE) Recife, PE, Brazil.
  • Hospital da Criança de Brasília José de Alencar, Brasília, DF, Brazil.
  • Hemocentro de Ribeirão Preto, USP, Ribeirão Preto, SP, Brazil.
  • Programa de Doença Falciforme do Centro Municipal de Saúde Leonidia Ayres Barreiras, BA, Brazil.
  • Hemocentro de Goiânia (HEMOLABOR), Goiania, GO, Brazil.
  • Fundação de Hematologia e Hemoterapia do Amazonas, Secretaria de Saúde do Amazonas, Manaus, AM, Brazil.
  • Fundação Hemocentro de Rondônia, Porto Velho, RO, Brazil.
  • Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
  • Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, PR, Brazil.
  • Universidade Federal do Mato Grosso do Sul, Campo Grande, MS, Brazil.
  • Hemocentro Coordenador do Estado do Rio de Janeiro (HEMORIO), Rio de Janeiro, RJ, Brazil.
  • St. Jude Children's Research Hospital, Menphis, TN, USA.
  • Coordenação Geral de Sangue e Hemoderivados do Ministério da Saúde, Brasilia, DF, Brazil.
  • Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
  • Hemorrede do Tocantins, Palmas, TO, Brazil.
  • Hemocentro do Macapá (HEMOAP), AP, Brazil.
  • Hemocentro de Santa Catarina (HEMOSC), Hospital Universitário (UFSC), Florianópolis, SC, Brazil.
  • Fundação Hemominas, Belo Horizonte, MG, Brazil.
  • HEMOPAC, Maceió, AL, Brazil.
  • Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brazil.
  • Instituto de Puericultura e Pediatria Martagão Gesteira (IPPMG), Rio de Janeiro, RJ, Brazil.
  • Universidade de Campinas (UNICAMP), São Paulo, SP, Brazil.
  • Grupo GSH, São Paulo, SP, Brazil.
  • Centro de referência em doença falciforme de Itabuna, Itabuna, BA, Brazil.

Abstract

To date, hydroxyurea is the only effective and safe drug that significantly reduces morbidity and mortality of individuals with Sickle cell disease. Twenty years of real-life experience has demonstrated that hydroxyurea reduces pain attacks, vaso-occlusive events, including acute chest syndrome, the number and duration of hospitalizations and the need for transfusion. The therapeutic success of hydroxyurea is directly linked to access to the drug, the dose used and adherence to treatment which, in part, is correlated to the availability of hydroxyurea. This consensus aims to reduce the number of mandatory exams needed to access the drug, prioritizing the requesting physician's report, without affecting patient safety.

MeSH

Cells, Hematology, Blood, Anemia, Sickle Cell, Pharmaceutical Preparations, Therapeutics, Hydroxyurea

Cited by